Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Cipla
Baxter
US Army
Express Scripts
AstraZeneca
Mallinckrodt
Argus Health
Harvard Business School

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,393,208

« Back to Dashboard

Which drugs does patent 9,393,208 protect, and when does it expire?

Patent 9,393,208 protects VIMOVO and is included in one NDA.

This patent has thirty-five patent family members in twenty-two countries.
Summary for Patent: 9,393,208
Title:Method for delivering a pharmaceutical composition to patient in need thereof
Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof.
Inventor(s): Ault; Brian (Wilmington, DE), Orlemans; Everardus (Chapel Hill, NC), Plachetka; John R. (Chapel Hill, NC), Sostek; Mark (Wilmington, DE)
Assignee: Pozen Inc. (Chapel Hill, NC) Horizon Pharma USA, Inc. (Deerfield, IL)
Application Number:14/980,639
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Dosage form;

Drugs Protected by US Patent 9,393,208

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT ➤ Try a Free Trial
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,393,208

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,220,698 Method for delivering a pharmaceutical composition to patient in need thereof ➤ Try a Free Trial
9,161,920 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Try a Free Trial
8,557,285 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Try a Free Trial
8,852,636 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,393,208

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 474559 ➤ Try a Free Trial
Australia 2002305758 ➤ Try a Free Trial
Australia 2006235929 ➤ Try a Free Trial
Australia 2009200966 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Dow
Healthtrust
Chubb
Citi
Queensland Health
Cantor Fitzgerald
Covington
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.